Compare · CMPS vs CMPX
CMPS vs CMPX
Side-by-side comparison of COMPASS Pathways Plc (CMPS) and Compass Therapeutics Inc. (CMPX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. CMPS focuses on Biotechnology: Pharmaceutical Preparations, while CMPX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- CMPS is the larger of the two at $1.81B, about 4.6x CMPX ($394.4M).
- Over the past year, CMPS is up 276.7% and CMPX is down 26.3% - CMPS leads by 302.9 points.
- CMPS has been more active in the news (7 items in the past 4 weeks vs 3 for CMPX).
- CMPX has more recent analyst coverage (24 ratings vs 16 for CMPS).
- Company
- COMPASS Pathways Plc
- Compass Therapeutics Inc.
- Price
- $13.39+1.59%
- $2.19-3.52%
- Market cap
- $1.81B
- $394.4M
- 1M return
- +17.25%
- +9.50%
- 1Y return
- +276.65%
- -26.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 7
- 3
- Recent ratings
- 16
- 24
COMPASS Pathways Plc
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest CMPS
- COMPASS Pathways upgraded by Evercore ISI with a new price target
- COMPASS Pathways Plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
- A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
- Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Karydas Daphne
- SEC Form 4 filed by Director Santini Gino
Latest CMPX
- Compass Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ladenburg Thalmann resumed coverage on Compass Therapeutics with a new price target
- A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
- Compass Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Compass Therapeutics to Participate in Upcoming June Investor Events
- Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
- Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.
- Compass Therapeutics to Participate in Upcoming May Investor Events
- SEC Form 10-Q filed by Compass Therapeutics Inc.